COYA on Nasdaq

Coya Therapeutics, Inc.

American pharmaceutical preparations company based in Houston. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Cogent Biosciences, Inc., RedHill Biopharma Ltd. or Aclaris Therapeutics, Inc., or pick any stock.

  • TickerCOYA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersHouston, Texas1
  • Incorporated inDE2
  • Business address12645 Memorial Dr., Suite F1 #305, Houston, Tx 770242
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

All references in this report to "Coya," the "Company," "we," "us," or "our" mean Coya Therapeutics, Inc. unless stated otherwise or the context otherwise indicates.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-283.9%Operating margin4
-267.1%Net margin4
123.6%Revenue growth, 20254
-49.3%Return on equity4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs100¢$7.9M
  • Income tax0¢$3.1K

Out of $7.9M in revenue.4 The company lost money this year.

Financial statements

Revenue564$7.9M in 2025
0$2.0M$4.0M$6.0M$8.0M2022: $0$020222023: $6.0M$6.0M20232024: $3.6M$3.6M2024−41%2025: $7.9M$7.9M2025+124%
Operating income7564-$22.6M in 2025+363% since 2021
-$30.0M-$20.0M-$10.0M02021: -$4.9M-$4.9M20212022: -$9.8M-$9.8M2022+101%2023: -$7.9M-$7.9M2023−19%2024: -$17.2M-$17.2M2024+118%2025: -$22.6M-$22.6M2025+31%
Net income7564-$21.2M in 2025+334% since 2021
-$30.0M-$20.0M-$10.0M02021: -$4.9M-$4.9M20212022: -$12.2M-$12.2M2022+150%2023: -$8.0M-$8.0M2023−35%2024: -$14.9M-$14.9M2024+86%2025: -$21.2M-$21.2M2025+43%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Collaboration revenue$7.9M$3.6M
Research and development$16.7M$11.9M
In-process research and development$2.3M$25.0K
General and administrative$11.4M$8.9M
Depreciation$27.4K$27.4K
Total operating expenses$30.5M$20.8M
Loss from operations-$22.6M-$17.2M
Other income$1.3M$1.6M
Pre-tax loss-$21.2M-$15.6M
Income tax (expense) benefit-$3.1K$720.3K
Net loss-$21.2M-$14.9M
Net loss per share of common stock, basic-$1.27-$0.98
Net loss per share of common stock, diluted-$1.27-$0.98
Weighted-average shares of common stock outstanding, basic16.7M shares15.2M shares
Weighted-average shares of common stock outstanding, diluted16.7M shares15.2M shares

Compare Coya Therapeutics, Inc. with another company

Leadership

Who has led Coya Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Howard Berman2022–2024
  2. Arun Swaminathan2024–now

Chair

  1. Howard Berman2026–now

Chief financial officer

  1. David S. Snyder2022–now
2025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerGreg MacMichael named May 20, 202222
  • DirectorAnn Lee named May 20, 2022 to Oct 28, 202423
  • DirectorWilbur Ross named Dec 20, 2023 to Oct 28, 202423

Timeline

  1. Nov 12, 2024New chief executive Arun Swaminathan becomes CEO10
  2. Dec 28, 2022New chief executive Howard Berman becomes CEO11

Filings

229 filings to the SEC since October 2021: 6 annual reports, 11 quarterly reports, 55 major events, 68 insider forms, 15 large holders, 3 private raises, 71 other. The latest 20:

  1. Oct 14, 20268-K EDGAR
  2. Oct 5, 20268-K EDGAR
  3. Sep 15, 20268-K EDGAR
  4. Aug 11, 202610-Q EDGAR
  5. Aug 11, 20268-K EDGAR
  6. Aug 7, 20268-K/A EDGAR
  7. Jul 27, 2026SCHEDULE 13G/A EDGAR
  8. Jun 25, 20268-K EDGAR
  9. May 13, 2026ARS EDGAR
  10. May 13, 2026DEFA14A EDGAR
  11. May 13, 2026DEF 14A EDGAR
  12. May 12, 20268-K EDGAR
  13. May 12, 2026424B5 EDGAR
  14. May 12, 202610-Q EDGAR
  15. May 12, 20268-K EDGAR
  16. Apr 9, 20264 EDGAR
  17. Apr 9, 20263 EDGAR
  18. Apr 2, 20268-K EDGAR
  19. Mar 20, 2026EFFECT EDGAR
  20. Mar 20, 2026424B3 EDGAR

The 229 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

12 open-market trades by officers, directors and large owners since October 2021: 12 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 14, 2024SNYDER DAVID SChief Financial OfficerBuy1,800$7.19$12.9KForm 4
Nov 13, 2024Swaminathan ArunChief Executive OfficerBuy5,000$7.36$36.8KForm 4
Nov 11, 2024Grossman FredChief Medical OfficerBuy2,710$7.37$20.0KForm 4
Nov 11, 2024Swaminathan ArunChief Executive OfficerBuy5,000$7.34$36.7KForm 4
Aug 22, 2023Lee AnnDirectorBuy1,000$3.62$3.6KForm 4
Jan 3, 2023Berman HowardExecutive ChairmanBuy10,000Form 4
Jan 3, 2023Lee AnnDirectorBuy10,000Form 4
Jan 3, 2023Hepner AdrianChief Medical OfficerBuy10,000Form 4
Jan 3, 2023SNYDER DAVID SChief Financial OfficerBuy7,000Form 4
Jan 3, 2023Garren HidekiDirectorBuy2,000Form 4
Jan 3, 2023Villalobos AnabellaDirectorBuy10,000Form 4
Jan 3, 2023GOLDSTEIN DOV A MDDirectorBuy10,000Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 23, 2024Raised $10 million in a private offering of equity Form D: 9 investors so far Form D
  2. Dec 5, 2023Raised $26.5 million in a private offering of equity Form D: 122 investors so far Form D
  3. Apr 5, 2022Raised $10.4 million in a private offering of debt Form D: $20 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 54. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
DME Capital Management, LP2,335,540$13.7M0.3%No change
Vanguard Capital Management LLC842,220$4.9M0.0%−2,693
Alyeska Investment Group, L.P.800,000$4.7M0.0%No change
AIGH Capital Management LLC631,912$3.7M0.3%−343,492
CM Management, LLC400,000$2.3M1.5%+25,000
Private Management Group Inc384,217$2.2M0.1%+15,121
Marshall Wace, Llp249,793$1.5M0.0%+24,001
Geode Capital Management, LLC228,243$1.3M0.0%−5,159
Renaissance Technologies LLC192,986$1.1M0.0%+89,022
Prosight Management, LP170,000$994.5K0.2%−250,360
Dimensional Fund Advisors LP155,917$913.0K0.0%+59,998
Vanguard Fiduciary Trust Co129,551$757.9K0.0%−10,335
Jones Financial Companies Lllp110,910$610.0K0.0%+65,950
BlackRock, Inc.102,408$599.1K0.0%+19,639
Prelude Capital Management, LLC101,330$592.8K0.0%No change
JBF Capital, Inc.100,006$585.0K0.1%No change
Royal Bank Of Canada93,414$546.0K0.0%+80,022
Morgan Stanley82,106$480.3K0.0%−3,594
State Street Corp79,813$466.9K0.0%No change
Susquehanna International Group, Llp61,006$356.9K0.0%+21,690
Northern Trust Corp45,072$263.7K0.0%+4,654
XTX Topco Ltd41,401$242.2K0.0%−5,937
ADAR1 Capital Management, LLC40,900$239.3K0.0%No change
Long Corridor Asset Management Ltd38,766$226.8K0.1%No change
Cetera Investment Advisers34,000$198.9K0.0%+4,000

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29